Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427539 | 0.90 | FAAH (0.53) | AKR1C3AKR1C1MTNR1AMTNR1BANPEP | |
| SCHEMBL367535 | 0.90 | FAAH (0.53) | AKR1C3AKR1C1MTNR1AMTNR1BANPEP | |
| SCHEMBL5608206 | 0.90 | FAAH (0.53) | AKR1C3AKR1C1MTNR1AMTNR1BANPEP | |
| Hydrochloric Acid SCHEMBL9266537 | 0.88 | ANPEP (0.53) | AKR1C3AKR1C1MTNR1AMTNR1BANPEP | |
| SCHEMBL17803291 | 0.80 | MTNR1A (0.49) | MTNR1AMTNR1BANPEPFAAHPLAU | |
| SCHEMBL22785039 | 0.80 | MTNR1A (0.53) | MTNR1AMTNR1BANPEPFAAHNOTUM | |
| SCHEMBL3525109 | 0.78 | MME (0.45) | MTNR1AMTNR1BANPEPFAAHPOLB | |
| SCHEMBL8547660 | 0.78 | GRIN2B (0.64) | — | |
| SCHEMBL6501529 | 0.78 | HTR7 (0.46) | RAB9ANPC1AKR1C3AKR1C1POLB | |
| SCHEMBL17803288 | 0.78 | IDH1 (0.50) | FAAHL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-09-26 | — | — | US | disclosed |
| US-20210040059-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | Institut National de la Santé et de la Recherche Médicale (FR) | 2021-02-11 | — | — | US | disclosed |
| EP-3749650-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | disclosed |
| EP-3226690-B1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019154956-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| US-10086000-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170360800-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362220-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3226690-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-3226689-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016089830-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089833-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362220-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | IDH3A, IDH3B, IDH2 | RAB9A 3830/4885NPC1 2842/4885AKR1C3 92/4885 |
| US-20170360800-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | IDH3A, IDH3B, IDH2 | RAB9A 4078/4885NPC1 3027/4885AKR1C3 41/4885 |
| US-20210040059-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | RAB9A 1953/4885NPC1 320/4885AKR1C3 3053/4885 |
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | RAB9A 1953/4885NPC1 320/4885AKR1C3 3053/4885 |
| US-10086000-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | IDH3A, IDH3B, IDH2 | RAB9A 4145/4885NPC1 2891/4885AKR1C3 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.